ABSTRACT. In this study, we investigated the antidepressant effects of hippocampal neuron administration of β-asarone, a selective mitogen-activated protein kinase phosphatase-1 inhibitor, in a rat model of depression. Our previous studies showed that the extracellular signal-regulated kinase signaling pathway and brain-derived neurotrophic factor expression, which is regulated by extracellular signal-regulated kinase, are key links in the biological mechanism of depression. Mitogen-activated protein kinase phosphatase-1 (MKP-1) is a negative regulatory protein of extracellular signal-regulated kinase signaling pathways. In this study, we explored the regulation of MKP-1 by β-asarone in producing an antidepressant effect.
INTRODUCTION
Acorus gramineus is a well-known Chinese traditional medicine that has been traditionally used for hundreds of years in oriental prescriptions for sedation as well as to enhance brain function (Vohora et al., 1990; Cho et al., 2002; Lim et al., 2012) . The major constituents of the essential oil from A. gramineus include β-asarone and phenylpropenes. In our preliminary study, β-asarone showed significant antidepressant effects.
Depression is one of the most common neuropsychiatric comorbidities, affecting approximately 10% of the population, and is the leading cause of disability worldwide (Yi et al., 2012) . Mitogen-activated protein kinase (MAPK) and MAPK phosphatase (MKP) are involved in drug addiction and depression (Jeanneteau and Deinhardt, 2011; Jia et al., 2013) . The extracellular signal-related kinase (ERK) signaling pathway is a classic MAPK signaling pathway and has been linked with synaptic plasticity and the survival of neurons (Grewal et al., 1999; Sweatt, 2001) ; sustained disruption of this pathway via MKP-1 is expected to have negative consequences on hippocampal neuron function (Boutros et al., 2008; Duric et al., 2010; Lee et al., 2012; Chen et al., 2012) . Our previous study showed that MKP-1 is involved in the antidepressant effects of β-asarone; however, the mechanism underlying its antidepressant effects has not been clearly demonstrated. In this study, we found that β-asarone exhibited neuroprotective effects by modulating the level of phosphorylated ERK1/2 (p-ERK1/2) and brain-derived neurotrophic factor (BDNF) by regulating the level of MKP-1. We found that inhibition of ERK activity occurred through the induction of the ERK inhibitor MKP-1. This led to an increase in the death of hippocampal neurons, which agree with the results obtained in a previous study following a chronic unpredictable mild stress (CUMS) study in which MKP-1 was upregulated (Qi et al., 2006) . Furthermore, downregulation of p-ERK1/2 or upregulation of MKP-1 enhanced hippocampal neuron apoptosis. In addition, we showed that downregulation of p-ERK1/2 or upregulation of MKP-1 decreased the basal level of BDNF protein and that inhibition of BDNF activity sensitized hippocampal neurons to β-asarone.
MATERIAL AND METHODS

Drugs and antibodies
Fluoxetine was produced by Suzhou Yushi Pharmaceutical Co., Ltd. (Suzhou, China). β-asarone was purchased from Tianjing Yifang Science and Technology Co., Ltd. (Yifang, China). Fluoxetine was dissolved in sterile saline (0.9%) and β-asarone was dissolved in double-distilled water at the required dose. Immunohistochemical staining kits for MKP-1, p-ERK1/2, and BDNF were purchased from Fuzhou Maixin Biotechnology Co., Ltd. (Fujian, China). The SYBR ® ExScript™ reverse transcription-polymerase chain reaction (RT-PCR) kit (Perfect Real Time) and RNAiso Reagent were purchased from Takara Co., Ltd. (Dalian, China). Antibodies for MKP-1, p-ERK1/2, and BDNF were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Animals
and water ad libitum for one week. Rats were housed at a temperature of 20° ± 2°C and humidity of 50 ± 5% in a controlled room with a 12-h light-dark cycle (lights on at 8:00 a.m.). All experimental procedures were conducted in conformity with the Institutional Animal Care and Use Committee (IACUC) guidelines.
Groups and treatment
In an open-field test, 60 SD rats were randomly divided into 4 groups (15 rats in each group). The normal control group (NC) was given no stress except general handing; the model control group (MC) was exposed to CUMS and given once daily oral gavage of physiological saline; the fluoxetine control group (FC) was exposed to CUMS and given once daily oral gavage (p.o.) administration of 1.2 mg/kg fluoxetine; and the β-asarone group (B) was exposed to CUMS and given once daily oral gavage (p.o.) administration of 25 mg/kg β-asarone. The NC group was conventionally fed in the manner of 5 animals per cage and other groups were fed in the manner of 1 animal per cage. The experiment lasted 4 weeks.
CUMS procedure
Rats in stressed groups were exposed to CUMS after a 1-week acclimatization period under the same housing conditions. CUMS procedures were based on previous studies (Willner et al., 1987; Duan et al., 2008) and included 9 types of stressors: food and water deprivation (24 h), cage tilt 45° (24 h), swimming in ice water (4°C, 5 min), tail clipping (3 min), cage rotation (cage shaken on a rocking bed, 30 min), day and night reversal, damp environment, heat stress (45°C, 5 min), and bounding. The stressors were given randomly 1 time daily and animals were not exposed to each stress factor more than 3 times. The stress sequence was changed every week in order to make the stress procedure unpredictable.
Behavior tests
Sucrose intake test
The sucrose intake test was a modified anhedonia-like state (Kessler et al., 2005) . Before the test, the rats were habituated to consume a 5% sucrose (Eckel et al., 2005) solution for 24 h without any water and food available. On the final stress day, the rats were deprived of water and food for 24 h. Then, the rats were given a 1-h window sucrose test (between 8:00 and 9:00 a.m.). Total sucrose consumption was measured after 1 h.
Open field test
The open field apparatus consisted of a black plywood box measuring 80 x 80 x 40 cm (width x length x height). The floor was divided into twenty-five 16 x 16-cm squares with white lines that had been drawn on the floor. A single rat was gently placed in the central square. The behaviors of rats were recorded for 3 min. The horizontal score (defined as at least 3 paws in a square) and the vertical score (defined as both frontal claws uplifting from the ground) were counted manually by 2 observers who were blinded to the experiment. Body weight was measured on days 1 and 28 of the experiment.
Immunohistochemistry
We randomly selected 6 rats in each group for immunohistochemical analysis. The rats were anesthetized with diethyl ether and perfused with 4% paraformaldehyde. The brain tissue was removed after perfusion fixation. Three-micrometer paraffin sections were incubated at 60°C for 30 min, then de-waxed and rehydrated with freshly distilled water for 2 min at room temperature. The sections were placed in a glass jar containing folic acid fluid for repair, pH 6.0, and heated in a pressure cooker to 125 kPa for 2 min. The sections were allowed to cool inside the pressure cooker for 20 min. After rinsing with double-distilled water, the sections were washed with phosphate-buffered saline (PBS), pH 7.4, for 3 min (3 times). Samples underwent inactivation of endogenous peroxidase for 15 min and were washed with PBS for 3 min (3 times). After removing PBS, samples were non-specifically blocked with normal goat serum for 15 min at room temperature. After removing the goat serum, rabbit anti-MKP-1 (1:50), p-ERK1/2 (1:150), and BDNF (1:100) antibody was added overnight at 4°C. Samples were flushed with PBS for 3 min (3 times). After removal of PBS, the samples were incubated with secondary antibody for 10 min at 37°C, and then flushed with PBS for 3 min (3 times). After removing the PBS, samples were incubated with the streptavidin-peroxidase complex for 10 min at 37°C, and then flushed with PBS for 3 min (3 times). After removal of PBS, peroxidase activity was developed using DAB as the chromogen, and then observed under a light microscope for 3-10 min. The samples were then stained with hematoxylin, dehydrated, and mounted for microscopic examination. Images of the sections were obtained (400X) using the Image-Pro Plus 4.5 software; brown cytoplasmic staining under light microscopy indicated a positive reaction for MKP-1, p-ERK1/2, and BDNF.
RT-PCR assay
Total RNA was extracted from the samples using TRIZOL reagent (Takara Biotechnology; Dalian, China). cDNA was synthesized (Takara Biotechnology) according to the manufacturer protocol. PCR was performed by using SYBR ® Premix Ex Taq TM in an ABI7300 real-time PCR system (Applied Biosystems; Foster City, CA, USA). The thermal profile was as follows: 1 cycle at 95°C for 10 s; 40 cycles for 5 s at 95°C and 31 s at 60°C. Threshold cycle (Ct) data were collected using the Sequence Detection Software version 1.2.3 (Applied Biosystems). Ct represents the cycle number at which a fluorescent signal rises statistically above background. The real-time PCR assay was performed in triplicate for each sample to ensure reproducibility. The relative quantification of gene expression was analyzed using the 2 -∆∆Ct method. The fold change in a target gene cDNA relative to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) internal control was determined by: fold change = 2 -∆∆Ct , where ∆∆ Ct = (Ct target gene -Ct GAPDH ) -(Ct control -Ct GAPDH ).
Statistical analysis
All data were analyzed using the SPSS 16.0 analysis software (SPSS, Inc.; Chicago, IL, USA). One-way analysis of variance test was performed to examine the data among groups. Means ± SE were compared with the least significant difference test for multiple β-asarone alleviates depression comparisons. Statistical significance was set at P < 0.05.
RESULTS
Effects of β-asarone treatment on body weight
On the first day of the experiment, there was no significant difference among groups in body weight (P > 0.05). After the 28-day stress procedure, a significant difference was observed among groups (P < 0.05). The MC group showed a significant decrease in body weight compared to the NC group (P < 0.05). β-asarone and fluoxetine treatments had a significant effect on the decrease in body weight (P < 0.05), suggesting that β-asarone affected body weight in CUMS rats ( Figure 1A ).
Effects of β-asarone treatment on sucrose intake
The sucrose intake test can be used to predict the sensitivity to rewards (Tõnissaar et al., 2006) . As shown in Figure 1B , the total consumption of sucrose was significantly lower in the MC group compared to the NC group. The total consumption of sucrose in the B and the FC groups were significantly increased compared to the MC group ( Figure 1B) . We found that β-asarone could increase the reward effect.
Effects of β-asarone treatment on the open field test
The open field test was used to study the exploratory and locomotor activity of rats (Prut and Belzung, 2003; Liu et al., 2013) . As shown in Figure 1 , on the first day of the experiment, there was no significant difference among groups in the open field test (P > 0.05) before the CUMS procedure. After 4 weeks of CUMS, the MC group showed significant depressive-like behaviors and a significant difference was observed among groups (P < 0.05). The MC group showed significantly lower scores for horizontal activity and vertical activity compared with the NC group (P < 0.05); compared with the MC group, the FC and B groups showed higher scores for horizontal activity and vertical activity (P < 0.05) (Figure 2A, B) . We found that behavior deficits induced by chronic stress were restored by β-asarone.
Effects of β-asarone treatment on MKP-1, p-ERK1/2, and BDNF levels in the hippocampus
Immunohistochemistry showed that the expression of MKP-1 in the MC group was comparable to that in the NC group (P < 0.05). However, the expression of p-ERK1/2 and BDNF in the FC and B groups was significantly decreased compared with that in the MC group (P < 0.05) ( Figure 3A, B, C) . The real-time RT-PCR assay showed that the expression of MKP-1 mRNA in the MC group was comparable to that in the NC group (P < 0.05). However, the expression of p-ERK1/2 mRNA and BDNF mRNA in the FC and B groups was significantly decreased compared with that in the MC group (P < 0.05) ( Figure  4A , B, C). On the first day of the experiment, there was no significant difference among groups (P > 0.05). After the experiment, we compared body weight and sucrose preference between the model control (MC) and normal control (NC) groups (*P < 0.05). Comparison between the MC, fluoxetine control (FC), and β-asarone (B) groups (**P < 0.05). Body weight: first day (F = 0.240, P = 0.868); 28th day (F = 48.162, P = 0.000). Total sucrose consumption: first day (F = 0.283, P = 0.838); 28th day (F = 37.302, P = 0.000). The level of MKP-1 protein in the MC group was significantly higher than that in other groups (F = 32.030, P = 0.000; *P < 0.05); the level of p-ERK1/2 and BDNF proteins in the MC group were significantly lower than those in other groups (p-ERK1/2: F = 14.681, P = 0.000, # P < 0.05; BDNF: F = 23.198, P = 0.000, # P < 0.05). MKP-1 mRNA levels in hippocampal neurons in the MC group were significantly higher than in the other groups (F = 85.727, P = 0.000, *P < 0.05); expression of p-ERK1/2 mRNA (B) and BDNF mRNA (C) was significantly lower than in the other groups (p-ERK1/2 mRNA: F = 212.940, P = 0.000, # P < 0.05; BDNF mRNA: F = 38.329, P = 0.000, # P < 0.05).
β-asarone alleviates depression
DISCUSSION
CUMS decreased body weight, induced anhedonia, and induced significant depressive-like behaviors. β-asarone reversed these effects and showed antidepressant effects. In this study, we found that β-asarone modulated neuronal survival by regulating the expression of MKP-1 in models of depression. Our data indicated the relevance of MKP-1 as a negative prognostic factor in the mechanism of depression. Overexpression of MKP-1 prevented ERK activity (low expression of p-ERK1/2) and downregulated the expression of BDNF. MKP-1 is not only directly expressed in response to stress, but is also a key negative regulator of the ERK signaling pathway, contributing to the expression of depressive symptoms (Vogt et al., 2005; Duric et al., 2010) . BDNF is well-known for its effects on axon outgrowth and branching (Cohen-Cory, 2002) . Indeed, the BDNF expression level is modulated by the ERK signaling pathway. Regulation of BDNF expression by MKP-1 is an important mechanism accounting for how neuronal networks may be refined in an activity-dependent manner (Glorioso et al., 2006; Jeanneteau et al., 2010) . The ERK signaling pathway has been examined for its role in stress and depression. Our findings showed that β-asarone treatment decreased MKP-1 and increased p-ERK1/2 and BDNF in the hippocampus of CUMS rats (P < 0.05). Our data showed that the ratio of MKP-1 in the hippocampus was significantly higher in the model group than that in the β-asarone and fluoxetine groups (P < 0.05). We also found that the ratio of p-ERK1/2 and BDNF in the hippocampus was significantly higher in the β-asarone and fluoxetine groups than in the model group (P < 0.05). β-asarone treatment appeared to have a stimulating effect on the experimental animals, and traditional medicine may be beneficial in model rats. Fluoxetine, a type of selective serotonin reuptake inhibitor, is a clinically effective antidepressant drug. In accordance with previous findings (Qi et al., 2006) , our results showed that fluoxetine alleviated anhedonia induced by chronic stress. In addition, we found that fluoxetine increased the levels p-ERK1/2 and BDNF in the hippocampus and decreased the level of MKP-1 in the hippocampus compared with the model group (P < 0.05). It is reasonable to speculate that β-asarone influences p-ERK1/2 and BDNF expression by mediating MKP-1, which has an antidepressant effect. Previous studies showed that β-asarone could effectively improve the weight and significantly improve behavior in a rat model of depression. We found that chronic stress exposure caused deficits in ERK and BDNF activation, but a surplus in MKP-1 activation in the hippocampus. This consequence could be reversed by β-asarone treatment. Our results suggested that β-asarone inhibits MKP-1 activation and sustains ERK signal pathway activation in rats exposed to CUMS, which may mediate the antidepressant-like effect of β-asarone. We identified MKP-1 as a key factor in depression pathophysiology and as a new target for therapeutic intervention.
